b'MyMRD Clinical InformationMinimal residual disease (MRD) detection has proven to beThe MyMRD is a hotspot panel that detects all classes of useful in the clinical management of patients with leukemiavariants identified in a precisely defined set of targets that and can facilitate the development of new therapies.commonly drive myeloid malignancies including AML, MPN Patients with myeloid neoplasms are typically divided intoand MDS. It can detect SNVs, indels and translocations to different prognostic groups based upon both cytogeneticsthe genomic base pair, yielding unparalleled precision and and traditional molecular profiles; 1however, this may notdetection of low level mutations in patients. The MyMRD assay, detects at least one driver mutation in 90%-95% of all reflect the heterogeneity of disease 2that can be exploitedAMLs. This gene panel is validated to a 5x10 -3level of detection using MRD assessment. Moreover, multiple sampling is notfor all targeted sites.feasible for many patients and thus the development of a sensitive and reliable assay to detect several mutations within one sample represents a significant advancement in guiding treatment decisions.List of Genes on the MyMRD Panel Structural Variants (Translocations and Partial TandemDuplications in Intronic Structures) SNV and Indel Targets in Genes (Exons) (23 genes) CBFB-MYH11 KMT2A RUNX1-RUNX1T1ASXL1 BRAF CALR CEBPA CSF3R DNMT3A FLT3 IDH1 IDH2 JAK2 KIT KMT2A KRAS MPL MYH11 NPM1 NRAS PTPN11 RUNX1 SF3B1 SRSF2 TP53 ZRSR2References1.Arber, DA et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acuteleukemia. Blood, 127(20):2391-2405.2.Sperling, AS et al. (2017). The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia.Nature Reviews. Cancer, 17(1):519. 52'